Share Twitter LinkedIn Facebook Email Jose F. Leis, MD, PhD, explains how Control of disease can be achieved with Ibrutnib High-risk Relapsed Refractory patients will progress at Imedex Great Debates 2018.
Sumanta (Monty) Kumar Pal, MD – Highlights and Insights from MOASC 2024 Summit: Pioneering Oncology Research and Celebrating Young Investigators General 3 Mins Read